The study is designed to evaluate the efficacy of CannTrust’s Cannabidiol Oil Capsules in slowing Amyotrophic Lateral Sclerosis (ALS) progression VAUGHAN, ON, July 11, 2018 /PRNewswire/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST), one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast […]

Zynerba Pharmaceuticals has launched a pivotal Phase 3 clinical trial, called CONNECT-FX, that will assess the safety and effectiveness of its cannabis-based ZYN002 as a potential therapy to treat behavioral symptoms in patients with fragile X syndrome. Top-line results from the trial are expected in the second half of 2019. ZYN002 is administered as a gel through […]

Zogenix, based in Emeryville, California, announced positive top-line data from its second confirmatory Phase III clinical trial of ZX008 (low-dose fenfluramine hydrochloride) for children and young adults with Dravet syndrome. Dravet syndrome is a rare form of epilepsy. The results from this second trial were consistent with the first, which hit the primary endpoint and […]

The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke. Dr. Sabet’s research will also analyze the effects of CannTrust CBD […]

CannTrust Holdings announced its involvement in a six-month clinical trial to determine the effectiveness of CBD oil capsules treating ALS or Motor Neuron Disease. CannTrust Holdings (TSX:TRST) announced its involvement in a six-month clinical trial to determine the effectiveness of cannabidiol (CBD) oil capsules treating Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). As quoted […]

The study is designed to evaluate the efficacy of CannTrust’s Cannabidiol Oil Capsules in slowing Amyotrophic Lateral Sclerosis (ALS) progression VAUGHAN, ON, July 11, 2018 /CNW/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST), one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast […]

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the initiation of a multi-national, randomized, double-blind placebo-controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD […]

TORONTO – June 27, 2018 (Investorideas.com Newswire) Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the treatment of autoimmune hepatitis […]

Paris, le samedi 7 juillet 2018 – Les tentatives de quelques buralistes et autres commerçants de profiter d’un flou juridique pour commercialiser des produits à base de chanvre (à faible teneur en THC mais riches en CBD) ont contribué à rouvrir les débats en France non pas sur la légitimité de l’autorisation du cannabis récréatif […]

Zynerba Pharmaceuticals has commenced the CONNECT-FX trial, a pivotal clinical trial designed to examine the efficacy and safety of ZYN002 to treat patients with Fragile X syndrome (FXS). The multi-national, randomised, double-blind placebo-controlled clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX) aims to enrol around 200 FXS patients aged between […]

Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa., July 09, 2018 (GLOBE NEWSWIRE) —  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative […]

A drug made from a derivative of marijuana has been approved for patients with certain forms of epilepsy. Blaine Harrington III/Getty Images hide caption toggle caption … read more at: https://www.npr.org/sections/health-shots/2018/06/25/623236189/fda-green-lights-marijuana-based-pharmaceutical-drug